TY - JOUR T1 - Autism Linked to Increased Oncogene Mutations but Decreased Cancer Rate. JF - PLoS One Y1 - 2016 A1 - Darbro, Benjamin W A1 - Singh, Rohini A1 - Zimmerman, M Bridget A1 - Mahajan, Vinit B A1 - Bassuk, Alexander G KW - Adolescent KW - Adult KW - Autism Spectrum Disorder KW - Child KW - Child, Preschool KW - Female KW - Genes, Tumor Suppressor KW - Genetic Predisposition to Disease KW - Humans KW - Infant KW - Male KW - Middle Aged KW - Mutation KW - Neoplasms KW - Oncogenes KW - Prevalence KW - Young Adult AB -

Autism spectrum disorder (ASD) is one phenotypic aspect of many monogenic, hereditary cancer syndromes. Pleiotropic effects of cancer genes on the autism phenotype could lead to repurposing of oncology medications to treat this increasingly prevalent neurodevelopmental condition for which there is currently no treatment. To explore this hypothesis we sought to discover whether autistic patients more often have rare coding, single-nucleotide variants within tumor suppressor and oncogenes and whether autistic patients are more often diagnosed with neoplasms. Exome-sequencing data from the ARRA Autism Sequencing Collaboration was compared to that of a control cohort from the Exome Variant Server database revealing that rare, coding variants within oncogenes were enriched for in the ARRA ASD cohort (p<1.0 x 10(-8)). In contrast, variants were not significantly enriched in tumor suppressor genes. Phenotypically, children and adults with ASD exhibited a protective effect against cancer, with a frequency of 1.3% vs. 3.9% (p<0.001), but the protective effect decreased with age. The odds ratio of neoplasm for those with ASD relative to controls was 0.06 (95% CI: 0.02, 0.19; p<0.0001) in the 0 to 14 age group; 0.35 (95% CI: 0.14, 0.87; p = 0.024) in the 15 to 29 age group; 0.41 (95% CI: 0.15, 1.17; p = 0.095) in the 30 to 54 age group; and 0.49 (95% CI: 0.14, 1.74; p = 0.267) in those 55 and older. Both males and females demonstrated the protective effect. These findings suggest that defects in cellular proliferation, and potentially senescence, might influence both autism and neoplasm, and already approved drugs targeting oncogenic pathways might also have therapeutic value for treating autism.

VL - 11 IS - 3 U1 - http://www.ncbi.nlm.nih.gov/pubmed/26934580?dopt=Abstract ER -